Health AI Central
Peer-Reviewed Publication
J Infect Dis2026October 9, 2026Journal Article

Translational and phase I evaluation of AZD0292, a novel, half-life extended anti-Pseudomonal Psl-PcrV bispecific monoclonal antibody.

Engin L1, Camille Riff2, Antonio DiGiandomenico3, Fred Reid4, Liesel Dsilva5, Margaret Kehl6, John Kim6, Mun Mun Patnaik3, Ashley Elaine Keller3, Rikard Pehrson7, Sanna Rosengren1, Jieqiang Zhou8, Marianna Stamou9, Huixia Zhang8, Patricia C Ryan10, Richard Baldry11, Gabriel Abreu12, Mushtaq Husain13, Karen Cartwright14, Isabelle de Mendez15, Ronald Goldwater16, Wayne Brailsford17, Rod Hughes4
1Early Clinical Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
2Clinical Pharmacology & Quantitative Pharmacology, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
3Microbial Antibodies and Technologies, Infectious Disease, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, USA.
4Early Clinical Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
5Global Patient Safety, Infectious Disease, AstraZeneca, Gaithersburg, USA.
6Bacterial Vaccines, Infectious Disease, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, USA.
7DMPK, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
8Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Gaithersburg, USA.
9Oncology Safety Sciences, BioPharmaceuticals R&D,  AstraZeneca, Waltham, USA.
10Immune Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, USA.
11Clinical Pharmacology & Quantitative Pharmacology, Post Marketing and Lifecycle Management, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
12Early Respiratory & Immunology Biometrics, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
13Integrated Bioanalysis, BioPharmaceuticals R&D, AstraZeneca, , Gaithersburg, USA.
14Bioethics, Chief Medical Office, Oncology R&D, AstraZeneca, Cambridge, UK.
15Global Portfolio and Project Management, AstraZeneca, Cambridge, UK.
16Parexel Early Phase Clinical Unit, Baltimore, USA.
17Projects, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
PubMed DOI

Abstract

BACKGROUND: Chronic Pseudomonas aeruginosa airway colonization in bronchiectasis (BE) is associated with frequent exacerbations. Bispecific antibody AZD0292, targeting P. aeruginosa Psl and PcrV, was engineered from gremubamab with a Fc N3Y substitution to extend half-life and is being developed to reduce exacerbations in BE with chronic P. aeruginosa colonization. METHODS: Preclinical studies as…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.